Results Out of the 73 aPL positive patients:
- 21% were positive for αβ2GPI, αD1 and αDIV/V;
- 41% were positive for αβ2GPI and αD1 but negative for αDIV/V;
- 4% were positive for αβ2GPI and αDIV/V but negative for αD1;
- 21% were αβ2GPI positive only;
- 4% were positive for αDIV/V;
- 9% were negative for antibodies against the whole molecule and the studied domains.

The prevalence of αD1 was 74% among patients with thrombotic pAPS and 60% among women with obstetric manifestations. 40% of aPL asymptomatic carriers were positive for αD1.

We observed a strong correlation between αβ2GPI and αD1 (p < 0.01, r = 0.536) but not αDIV/V (p = 0.07, r = 0.216).

Conclusions Most of the αβ2GPI positive sera displayed reactivity against D1, while αDIV/IV were detected in a low rate of patients. Our data suggest that D1 is the immunodominant β2GPI epitope and that αD1 are the main antibody population in APS patients. Future studies are warranted to better define the diagnostic and prognostic role of anti-D1 in APS.

A5.6 ANTI-CARbamylated PROTEIN ANTIBodies ARE PRESENT IN MICE WITH COLLAGEN INDUCed ARTHRITIS doi:10.1136/annrheumdis-2013-203219.6
Jeroen Stoop, Bisheng Liu, Jing Shi, Diahann Jansen, Leendert Trouw, Rene Toes. Dept. of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

Objective Antibodies against citrullinated proteins (ACPAs) are a characteristic of rheumatoid arthritis (RA). Carbamylation is a different type of post translational modification, where a lysine amino acid is converted into a homocitrullin. Recently we identified antibodies binding to carbamylated proteins (anti-CarP) in a subgroup of RA patients. In ACPA negative RA patients anti-CarP antibodies associate with joint damage.

The Aim of this study was to determine whether these anti-CarP antibodies are present in animal models of arthritis.

Methods Collagen induced arthritis (CIA) was induced in DBA/1 (n = 29) and C57Bl/6 (n = 20) mice by immunisation with type II collagen in CFA. Arthritis severity was monitored using a clinical scoring system. Non-immunised animals (n = 9) served as negative controls. After disease onset serum was harvested and antibody levels were determined by ELISA. The specificity of our anti-CarP ELISA was validated using dotblots.

Results Whereas no anti-CarP antibodies could be detected in non-immunised DBA/1 mice, anti-CarP total Ig was present in 93% of the arthritic mice. Of those mice 59% had IgG1 and 79% had IgG2a anti-CarP antibodies. Antibodies to citrullinated proteins could not be detected. The levels of mouse collagen-specific IgG2a correlated with the clinical score. However, the levels of the different anti-CarP isotypes did not. Around 60% of the immunised C57Bl/6 mice developed arthritis. Anti-CarP IgG2c could be detected in 55% of those mice and could not be detected in the mice that did not get CIA. Anti-CarP IgG1 was detected in 28% of the arthritic mice. Interestingly, mouse collagen specific IgG2c antibodies were detected in 100% of the immunised C57Bl/6 mice. Dotblot analysis, using carbamylated and non-modified proteins confirmed the ELISA results regarding the specificity of the antibodies for homocitrulline containing proteins.

Conclusions Mice with CIA have antibodies to carbamylated proteins and their presence associated with disease development. All immunised mice have anti-mouse CII antibodies, indicating that the presence of anti-CarP antibodies could be a disease specific marker for arthritis in mice. Further studies will be required to determine the role of anti-CarP in the pathogenesis of arthritis.

A5.7 AUTOANTIBODIES TO THE FIBRIN-DERIVED CITRULLINATED PEPTIDES α36–50 AND β60–74 ARE TWO DISTINCT NON-OVERLAPPING SUBFAMILIES OF ACPA THAT TOGETHER ALWAYS SUMMARISE THEIR REACTIVITY TO CITRULLINATED FIBRINOGEN AND TO CCP2 ANTIGENS doi:10.1136/annrheumdis-2013-203219.7
1M Cornillet, 1M Sebbag, 2E Verroul, 1A Magyar, 2A Ryussen-Erritrand, 2F Hudetz, 2A Cantagrel, 1G Serre, 1L Nagoueira. "Laboratory of "Epidermis Differentiation and Rheumatoid Autoimmunity", UMR CNRS 5165, INSERM U 1056, Toulouse III University; 2Rheumatology Center, University Hospital of Toulouse; Laboratory of Cell Biology and Cytology, University Hospital of Toulouse, Toulouse, France; 3Research Group of Peptide Chemistry, Department of Organic Chemistry, Hungarian Academy of Sciences, Eötvös Loránd University, Budapest, Hungary

Objectives To evaluate the proportions of Rheumatoid Arthritis (RA) sera containing autoantibodies to citrullinated proteins (ACPA) reactive to α36–50 and/or β60–74 two citrullinated peptides identified as bearing the immunodominant epitopes of their major target: citrullinated fibrin. To analyse the relationships of anti-α36–50 and anti-β60–74 autoantibodies with autoantibodies to the whole citrullinated human fibrinogen (AhFibA) and with anti-CCP2 antibodies. Methods 617 sera from 181 established RA and 436 non-RA rheumatologic patients were tested by ELISA for AhFibA, anti-CCP2, anti-α36–50, anti-β60–74 autoantibodies, and by nephelometry for Rheumatoid Factor (RF). Diagnostic indexes, correlations and concordances between tests were analysed. Cross-reactivity between anti-α36–50 and anti-β60–74 autoantibodies was assessed with peptide absorption experiments.

Results At diagnostic specificity of 95%, the diagnostic sensitivity of AhFibA (85%) was significantly higher than that of all other tests. The diagnostic sensitivity of anti-β60–74 autoantibodies (71%) was significantly higher than that of anti-α36–50 (51%) but similar to that of anti-CCP2 (74%). Titres of RF, anti-α36–50 and anti-β60–74 autoantibodies were weakly correlated with each other, whereas titres of anti-β60–74 were strongly correlated with those of AhFibA (rho = 0.633) and of anti-CCP2 (rho = 0.654). More than 90% of AhFibA-positive or anti-CCP2-positive sera recognised the α36–50 and/or the β60–74 peptide. Absorption experiments showed that anti-α36–50 and anti-β60–74 mainly correspond to non-cross reactive subfamilies of ACPA.

Conclusions Autoantibodies to α36–50 and β60–74 are two distinct non-overlapping subfamilies of ACPA that together almost summarise the ACPA reactivity to citrullinated fibrinogen and to CCP2 antigens. In established RA, anti-β60–74 autoantibodies show diagnostic indexes similar to those of anti-CCP2.

A5.8 B CELL DEPLETION THERAPY IN A COHORT OF PATIENTS WITH SEROPOSITIVE AND SERONEGATIVE RHEUMATOID ARTHRITIS doi:10.1136/annrheumdis-2013-203219.8
ML Vellosa Feijoo, R Martinez Pérez, L Mayordomo Gonzalez, JL Marenco de la Fuente. Rheumatology Unit, Valme University Hospital, Seville, Spain

Background B cells play a crucial role in the pathogenesis of rheumatoid arthritis (RA). They are responsible for the autoantibodies formation such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibodies (anti-CCP) and the production of cytokines, act as antigen presenting cells and regulate T cell functions.

Rituximab (RTX), murine monoclonal antibody which selectively targets CD20-positive B-cells, has proved to be an effective and safe therapy for active RA. Initially it was used in seropositive RA, but considering the other functions of B cells, it is logical to think that it is also useful in seronegative forms.
**Objective** To evaluate the efficacy of RTX in our series of refractory seronegative and seropositive RA.

**Materials and Methods** Baseline characteristics and disease activity markers at baseline, and after 3 and 6 months of treatment with RTX (1g x 2 weeks), were collected in 33 patients. A descriptive study was made, and the relations between variables were analysed statistically.

**Results** The mean age was 52.06 ± 12.01 years, 75.8% female, 78.8% RF positive. The mean duration of illness was 7.70 ± 4.47 years. Thirty-two patients (97%) had failed at least to one TNF antagonist.

The mean DAS28 at baseline was 5.7 ± 1.30, at 3 months decreased to 3.4 ± 1.22, and at 6 months to 4.15 ± 1.69 (p < 0.0005).

At 3 months, 88.9% reached good eular response, and 63.3% at 6 months. Remission was obtained in 17.2% at 3 months and in 16.7% at 6 months.

It was also noted improvement in baseline HAQ, after 3 and 6 months (from 1.75 ± 0.767 to 0.96 ± 0.56 and 1.24 ± 0.70 respectively).

No significant differences were found between decreases in DAS 28 at 3 and 6 months compared to baseline between RF seronegative and seropositive patients, neither in good eular response, remission percentages or HAQ improvement. The data are shown in the table.

**Discussion** The efficacy and safety of RTX has been proved in several clinical trials.

The presence of RF, low baseline functional disability and no more than one previous anti-TNF are predictors of good response to RTX, as has been recently published.

Response rates in seronegative RA are slightly lower, although higher than placebo, as described in other publications.

In conclusion, the experience of RTX treatment in our patients with seronegative RA is positive, in terms of efficacy, due to the action on B cells and their different roles, with no significant differences comparing to seropositive RA.

**Conclusions** Knowing the mean, medians and standard deviations of the B lymphocyte subpopulations subsets is important in helping to compare these results with those obtained in studies of patients with autoimmune diseases.

In most cases, conclusions drawn after the study with flow cytometry are based on knowing how these subpopulations vary with respect to healthy people in order to draw conclusions about what subpopulations are involved the most in the pathogenesis of the disease.

We believe, therefore, important to deepen in studies of this kind in order to clarify more situations of normality in the world of flow cytometry: a technique that is increasingly taking more importance in the understanding of autoimmune diseases.

**Abstract A5.9 Table 1**

<table>
<thead>
<tr>
<th>Subpopulations</th>
<th>Mean</th>
<th>Typical deviation</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Naive</td>
<td>70.46</td>
<td>8.06</td>
<td>73.70</td>
</tr>
<tr>
<td>DN</td>
<td>4.05</td>
<td>2.08</td>
<td>4.66</td>
</tr>
<tr>
<td>Unswitched Memory</td>
<td>9.65</td>
<td>5.33</td>
<td>10.05</td>
</tr>
<tr>
<td>switched Memory</td>
<td>11.38</td>
<td>4.62</td>
<td>11.00</td>
</tr>
<tr>
<td>Bm1</td>
<td>7.82</td>
<td>9.29</td>
<td>5.10</td>
</tr>
<tr>
<td>Bm2</td>
<td>73.14</td>
<td>10.71</td>
<td>73.05</td>
</tr>
<tr>
<td>PreGC</td>
<td>2.90</td>
<td>1.61</td>
<td>2.89</td>
</tr>
<tr>
<td>Bm3 + 4</td>
<td>0.56</td>
<td>0.53</td>
<td>0.44</td>
</tr>
<tr>
<td>Late Bm5</td>
<td>3.17</td>
<td>2.74</td>
<td>2.50</td>
</tr>
<tr>
<td>Early Bm5</td>
<td>9.12</td>
<td>4.93</td>
<td>9.21</td>
</tr>
</tbody>
</table>

**Abstract A5.10 Δ4BAFF ALTERNATIVE SPLICING IS REGULATED BY IFN-γ AND SC35 PROTEIN**

doi:10.1136/annrheumdis-2013-203219.10

1Gabriel J Tobón, 2Laurent Corcos, 1Laëtitia Le Pottier, 2Gwendal Dujardin, 1Pierre Younou, 1Jacques-Olivier Pers. “EA2216 "Immunology & Pathology". INSERM, UMR1078, Brest University and European University of Brittany, Brest, France

**Background** The B-cell activating factor (BAFF) is a potent survival factor involved in the pathogenesis of autoimmune diseases. Recently, we reported the discovery of a new transcript for BAFF, Δ4BAFF – lacking exon 4 –, which is mainly detected in autoimmune diseases and acts as a transcription factor for its own gene. However, the mechanisms implicated in Δ4BAFF induction and up-regulation are unknown. In this study we analysed the induction and regulation of Δ4BAFF.

**Materials and Methods** First, to study the alternative splicing of BAFF exon 4, we transfected a minigene construct, centred on exon 4, into RAMOS B cells. To determine the proteins implicated in exon 4 inclusion/exclusion, we co-transfected the minigene together with each of the plasmids coding for the main splicing proteins.